To delineate the immunophenotypic signatures and clinical management of GIMAP5 deficiency by reporting a significant pediatric case and reviewing previously published patients to enhance understanding of the disorder.
Approach:
Key Findings:
The proband exhibited autoimmune cytopenias, severe viral infections, and liver anomalies, highlighting the severe impact of GIMAP5 deficiency.
Genetic analysis revealed compound heterozygous variants in the GIMAP5 gene, confirming the genetic basis of the disorder.
The dizygotic twin had a heterozygous variant but no immune defects, suggesting a potential protective effect or incomplete penetrance.
Sirolimus treatment led to sustained clinical remission of cytopenias, indicating a promising therapeutic avenue.
Interpretation:
The findings suggest complex genotype-phenotype interactions and highlight the potential for precision medical management in GIMAP5 deficiency, particularly through targeted therapies like sirolimus.
Limitations:
The study is based on a single case report and a review of previously published cases, which may limit generalizability to the wider population.
Potential environmental or epigenetic factors influencing the phenotype were not extensively explored, which could provide further insights into the disorder.
Conclusion:
The successful use of sirolimus indicates a promising targeted therapy approach, while the risks of HSCT remain significant due to pre-existing vascular fragility, necessitating careful patient selection.
by Mattia Moratti, Michele La Manna, Lucia Colucci, Cristina Cifaldi, Silvia Di Cesare, Gioacchino Andrea Rotulo, Beatrice Rivalta, Donato Amodio, Andrea Pietrobattista, Andrés Caballero-Oteyza, Elisabetta Lembo, Chiara Passarelli, Emma Concetta Manno, Michele Proietti, Gigliola Di Matteo, Giuseppe Palumbo, Caterina Cancrini
One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.
